XML 59 R45.htm IDEA: XBRL DOCUMENT
v3.25.0.1

INCOME TAXES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Schedule of (Loss) Income before Taxes, Domestic and Foreign | (Loss) income before taxes consisted of the following:
| As of December 31,
(in thousands) | 2024 |  | 2023 |  | 2022
Domestic | $ | (24,618) |  |  | $ | 19,124 |  |  | $ | (64,913) |
Foreign | 2,406 |  |  | 748 |  |  | 2,248 |
(Loss) income before income tax (benefit) expense | $ | (22,212) |  |  | $ | 19,872 |  |  | $ | (62,665) |
Schedule of Components of Income Tax Expense (Benefit) | Total income tax (benefit) expense for income taxes consists of the following for the years ended December 31:
| As of December 31,
(in thousands) | 2024 |  | 2023 |  | 2022
Current income tax expense |  |  |  |  |
Federal | $ | 13,714 |  |  | $ | 9,117 |  |  | $ | 152 |
State | 2,231 |  |  | 3,534 |  |  | 249 |
Foreign | 1,876 |  |  | 26 |  |  | 66 |
Total | 17,821 |  |  | 12,677 |  |  | 467 |
Deferred income tax benefit |  |  |  |  |
Federal | (17,876) |  |  | (7,601) |  |  | (13,382) |
State | (3,906) |  |  | (3,946) |  |  | (1,722) |
Foreign | (1,217) |  |  | (29) |  |  | (128) |
Total | (22,999) |  |  | (11,576) |  |  | (15,232) |
Change in valuation allowance | 1,488 |  |  | (8) |  |  | (4) |
Total (benefit) expense for income taxes | $ | (3,690) |  |  | $ | 1,093 |  |  | $ | (14,769) |
Schedule of Effective Income Tax Rate Reconciliation | The difference between the expected income tax (benefit) expense from applying U.S. Federal statutory tax rates to the pre-tax (loss) income and actual income tax (benefit) expense relates primarily to the effect of the following:
| As of December 31,
| 2024 |  | 2023 |  | 2022
US Federal statutory rate | 21.0 | % |  | 21.0 | % |  | 21.0 | %
State taxes, net of Federal benefit | 2.5 | % |  | 4.8 | % |  | 3.2 | %
Foreign taxes | (3.0) | % |  | 0.0% |  | 0.1 | %
Change in valuation allowance | (6.7) | % |  | 0.0% |  | — | %
Stock-based compensation | (6.5) | % |  | 10.8 | % |  | (1.4) | %
Non-deductible costs | (8.8) | % |  | 2.1 | % |  | (0.5) | %
Change in state apportionment factors, state and foreign rates | 4.0 | % |  | (11.8) | % |  | (0.1) | %
Research and experimentation and charitable credits | 14.1 | % |  | (19.0) | % |  | 1.4 | %
Transfer pricing and other | — | % |  | (2.4) | % |  | (0.1) | %
Effective income tax rate | 16.6 | % |  | 5.5 | % |  | 23.6 | %
Schedule of Deferred Tax Assets and Liabilities | Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Deferred income tax assets and liabilities consisted of the following:
| As of December 31,
(in thousands) | 2024 |  | 2023
Deferred tax assets: |  |  |
Accruals and advances | $ | 16,318 |  |  | $ | 12,470 |
Stock-based compensation | 7,373 |  |  | 6,013 |
Accruals for chargebacks and returns | 23,427 |  |  | 17,358 |
Inventories | 5,234 |  |  | 4,569 |
Intangible assets | — |  |  | 40,193 |
Net operating loss carryforwards | 27,254 |  |  | 2,900 |
Capitalized research expenditures | 19,836 |  |  | 11,294 |
Interest expense carryforwards | 6,400 |  |  | 5,132 |
Debt instruments | 9,590 |  |  | — |
Other assets | 5,305 |  |  | 2,318 |
Total deferred tax assets | $ | 120,737 |  |  | $ | 102,247 |
Deferred tax liabilities: |  |  |
Depreciation | $ | (6,710) |  |  | $ | (5,658) |
Intangible assets | (12,537) |  |  | — |
Other liabilities | (6,934) |  |  | (5,440) |
Total deferred tax liabilities | $ | (26,181) |  |  | $ | (11,098) |
Valuation allowance | (9,450) |  |  | (438) |
Deferred tax assets, net of deferred tax liabilities and valuation allowance | $ | 85,106 |  |  | $ | 90,711 |
As of December 31, 2024, U.S. federal net operating loss carryforwards were approximately $55.6 million and UK net operating losses of approximately $50.8 million, primarily arose as a result of the acquisition of Alimera and the 2013 merger with BioSante Pharmaceuticals, Inc. Net operating loss carryforwards related to the 2024 acquisition are indefinite lived. Net operating loss carryforwards related to the 2013 merger, if not used, expire in annual increments through 2033. All of the net operating loss carryforwards are limited on an annual basis as prescribed by Section 382 of the U.S. Internal Revenue Code; the current annual limitation is approximately $7.2 million per year. Additionally, as of December 31, 2024, the Company has total net operating losses in various states of $5.7 million which begin to expire through 2042. The Company is subject to income taxes in numerous jurisdictions in the U.S. and certain foreign jurisdictions. Significant judgement is required in evaluating tax positions and determining the expense for income taxes. The Company established liabilities for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These liabilities are established when the Company believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjusts these liabilities in light of changing facts and circumstances, such as the outcome of a tax audit. The expense for income taxes includes the impact of changes to the liability that is considered appropriate. The Company has not identified any material uncertain income tax positions as of December 31, 2024 and 2023. The Company is subject to income tax audits in all jurisdictions for which tax returns are filed. Tax audits by their nature are often complex and can require several years to complete. All of the Company's income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details
Name: | us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details
Name: | us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details
Name: | us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of income before income tax between domestic and foreign jurisdictions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details
Name: | us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration